188 related articles for article (PubMed ID: 15254165)
1. Superinfection exclusion in duck hepatitis B virus infection is mediated by the large surface antigen.
Walters KA; Joyce MA; Addison WR; Fischer KP; Tyrrell DL
J Virol; 2004 Aug; 78(15):7925-37. PubMed ID: 15254165
[TBL] [Abstract][Full Text] [Related]
2. Viral and cellular determinants involved in hepadnaviral entry.
Glebe D; Urban S
World J Gastroenterol; 2007 Jan; 13(1):22-38. PubMed ID: 17206752
[TBL] [Abstract][Full Text] [Related]
3. Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection.
Miller DS; Boyle D; Feng F; Reaiche GY; Kotlarski I; Colonno R; Jilbert AR
Virology; 2008 Apr; 373(2):329-41. PubMed ID: 18206204
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility to duck hepatitis B virus infection is associated with the presence of cell surface receptor sites that efficiently bind viral particles.
Pugh JC; Di Q; Mason WS; Simmons H
J Virol; 1995 Aug; 69(8):4814-22. PubMed ID: 7609048
[TBL] [Abstract][Full Text] [Related]
5. Antiviral effects of PNA in duck hepatitis B virus infection model.
Chen ZY; Cheng AC; Wang MS; Xu DW; Zeng W; Li Z
Acta Pharmacol Sin; 2007 Oct; 28(10):1652-8. PubMed ID: 17883953
[TBL] [Abstract][Full Text] [Related]
6. DNA vaccines expressing the duck hepatitis B virus surface proteins lead to reduced numbers of infected hepatocytes and protect ducks against the development of chronic infection in a virus dose-dependent manner.
Miller DS; Kotlarski I; Jilbert AR
Virology; 2006 Jul; 351(1):159-69. PubMed ID: 16624364
[TBL] [Abstract][Full Text] [Related]
7. Effect of nucleoside analogue therapy on duck hepatitis B viral replication in hepatocytes and bile duct epithelial cells in vivo.
Nicoll A; Locarnini S; Chou ST; Smallwood R; Angus P
J Gastroenterol Hepatol; 2000 Mar; 15(3):304-10. PubMed ID: 10764033
[TBL] [Abstract][Full Text] [Related]
8. Decrease of wild-type and precore mutant duck hepatitis B virus replication during lamivudine treatment in white Pekin ducks infected with the viruses.
Tomita T; Yokosuka O; Tagawa M; Saisho H; Tamura S; Fukuda I; Omata M
J Hepatol; 2000 May; 32(5):850-8. PubMed ID: 10845674
[TBL] [Abstract][Full Text] [Related]
9. Envelope protein-mediated down-regulation of hepatitis B virus receptor in infected hepatocytes.
Breiner KM; Urban S; Glass B; Schaller H
J Virol; 2001 Jan; 75(1):143-50. PubMed ID: 11119583
[TBL] [Abstract][Full Text] [Related]
10. [Inhibition of binding peptides on replication of duck hepatitis B virus].
Jia HY; Chen Z; Zhou LF; Chen F; Zhu HH; Liu JH; Xu XY
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 34(2):116-20. PubMed ID: 15812883
[TBL] [Abstract][Full Text] [Related]
11. Duck hepatitis B virus (DHBV) infection in Indian domestic ducks: a pilot study.
Sridhar G; Valliammai T; Varalakshmi CS; Udayasankar K; Panchanadam M; Ramakrishna J; Gopal KV; Jayaraman K; Thyagarajan SP
Trop Anim Health Prod; 1993 Nov; 25(4):229-33. PubMed ID: 8109057
[TBL] [Abstract][Full Text] [Related]
12. Vaccination of ducks with a whole-cell vaccine expressing duck hepatitis B virus core antigen elicits antiviral immune responses that enable rapid resolution of de novo infection.
Miller DS; Halpern M; Kotlarski I; Jilbert AR
Virology; 2006 May; 348(2):297-308. PubMed ID: 16469347
[TBL] [Abstract][Full Text] [Related]
13. [Establishment of an in vivo model for duck hepatitis B virus infection using Hubei duckling].
Hu Q; Fang Y; Zhang ZM; Zhang XY; Zhang ZH; Yang DL
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Apr; 22(2):113-5. PubMed ID: 18574531
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the kinetics of the specific cellular immune response to duck hepatitis B virus in infected and immune ducks.
Vickery K; Cossart Y; Dixon R
Vet Microbiol; 1999 Aug; 68(1-2):157-69. PubMed ID: 10501173
[TBL] [Abstract][Full Text] [Related]
15. Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection.
Le Mire MF; Miller DS; Foster WK; Burrell CJ; Jilbert AR
J Virol; 2005 Oct; 79(19):12242-52. PubMed ID: 16160150
[TBL] [Abstract][Full Text] [Related]
16. DHBV manipulation and prediction of the outcome of infection.
Vickery K; Cossart Y
J Hepatol; 1996 Oct; 25(4):504-9. PubMed ID: 8912150
[TBL] [Abstract][Full Text] [Related]
17. Characterization of age- and dose-related outcomes of duck hepatitis B virus infection.
Jilbert AR; Botten JA; Miller DS; Bertram EM; Hall PM; Kotlarski J; Burrell CJ
Virology; 1998 May; 244(2):273-82. PubMed ID: 9601498
[TBL] [Abstract][Full Text] [Related]
18. Duck hepatitis B virus infection of Muscovy duck hepatocytes and nature of virus resistance in vivo.
Pugh JC; Simmons H
J Virol; 1994 Apr; 68(4):2487-94. PubMed ID: 7511172
[TBL] [Abstract][Full Text] [Related]
19. Cellular immune response of ducks to duck hepatitis B virus infection.
Vickery K; Cossart Y; Dixon R
J Med Virol; 1999 May; 58(1):19-25. PubMed ID: 10223541
[TBL] [Abstract][Full Text] [Related]
20. [Combination of lamivudine with thymosin alpha1 in treatment of duck hepatitis B].
Chen XM; Liu ZM; Du XF; Yang ZG; Chen XM
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 34(2):121-5. PubMed ID: 15812884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
